Eris Lifesciences Ltd (BOM:540596)
₹ 1367.75 43.05 (3.25%) Market Cap: 186.16 Bil Enterprise Value: 211.04 Bil PE Ratio: 53.47 PB Ratio: 6.71 GF Score: 95/100

Eris Lifesciences Ltd to Acquire Biocon Biologics Ltd Call Transcript

Mar 14, 2024 / 11:00AM GMT
Release Date Price: ₹863.5 (+3.99%)
Operator

Ladies and gentlemen, good day, and welcome to the Webcast of Eris Lifesciences Limited. We have with us on call today, Mr. Amit Bakshi, Chairman and Managing Director; and Mr. V. Krishnakumar, Chief Operating Officer and Executive Director.

As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. All the participants are requested to restrict the discussion to the deals announced today. Please note, this webcast is being recorded. I now hand the conference over to Mr. V. Krishnakumar, Chief Operating Officer and Executive Director of the company. Thank you and over to you, sir.

Krishnakumar Vaidyanathan
Eris Lifesciences Ltd - Chief Operating Officer, Executive Director

Good afternoon, everybody. Welcome to this webcast. We are here to talk about the two announcements we have made today. Eris proposes to acquire the India branded formulations business of Biocon Biologics and 19% stake in Swiss Parenterals from Eris Promoter Group. At the outset,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot